Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.
Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, Gibbons JA, Cheng SL, Delaria KA, Fleischer R, Greve JM, Gundel R, Harris K, Kelly R, Koh B, Li Y, Lantz L, Mak P, Neyer L, Plym MJ, Roczniak S, Serban D, Thrift J, Tsuchiyama L, Wetzel M, Wong M, Zolotorev A. Shanafelt AB, et al. Among authors: plym mj. Nat Biotechnol. 2000 Nov;18(11):1197-202. doi: 10.1038/81199. Nat Biotechnol. 2000. PMID: 11062441
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. Tenney DJ, et al. Among authors: plym mj. Antimicrob Agents Chemother. 2007 Mar;51(3):902-11. doi: 10.1128/AAC.00833-06. Epub 2006 Dec 18. Antimicrob Agents Chemother. 2007. PMID: 17178796 Free PMC article. Clinical Trial.
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. Tenney DJ, et al. Antimicrob Agents Chemother. 2004 Sep;48(9):3498-507. doi: 10.1128/AAC.48.9.3498-3507.2004. Antimicrob Agents Chemother. 2004. PMID: 15328117 Free PMC article.
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Colonno RJ, et al. Hepatology. 2006 Dec;44(6):1656-65. doi: 10.1002/hep.21422. Hepatology. 2006. PMID: 17133475 Clinical Trial.
BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties.
Tertyshnikova S, Knox RJ, Plym MJ, Thalody G, Griffin C, Neelands T, Harden DG, Signor L, Weaver D, Myers RA, Lodge NJ. Tertyshnikova S, et al. Among authors: plym mj. J Pharmacol Exp Ther. 2005 Apr;313(1):250-9. doi: 10.1124/jpet.104.078592. Epub 2004 Dec 17. J Pharmacol Exp Ther. 2005. PMID: 15608074
Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress-aggravated colonic motility and visceral nociception.
Sivarao DV, Newberry K, Langdon S, Lee AV, Hewawasam P, Plym MJ, Signor L, Myers R, Lodge NJ. Sivarao DV, et al. Among authors: plym mj. J Pharmacol Exp Ther. 2005 May;313(2):840-7. doi: 10.1124/jpet.104.079285. Epub 2005 Feb 8. J Pharmacol Exp Ther. 2005. PMID: 15701710
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
Surguladze D, Deevi D, Claros N, Corcoran E, Wang S, Plym MJ, Wu Y, Doody J, Mauro DJ, Witte L, Busam KJ, Pytowski B, Rodeck U, Tonra JR. Surguladze D, et al. Among authors: plym mj. Cancer Res. 2009 Jul 15;69(14):5643-7. doi: 10.1158/0008-5472.CAN-09-0487. Epub 2009 Jul 7. Cancer Res. 2009. PMID: 19584274